about
Targeting Hepatocellular Carcinoma: What did we Discover so Far?Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer.Dynamics of CD86 expression on allergic inflammation--new insights.Histologic evaluation of the effect of mineral trioxide aggregate-Fillapex as a root canal sealer in rat teeth submitted to late replantation.The role of vitamins in cancer: a review.Amniotic membrane: from structure and functions to clinical applications.Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.Retinoblastoma: might photodynamic therapy be an option?Bisphosphonate-related osteonecrosis of the jaw: specificities.Lung cancer: the immune system and radiation.Clinical translation for endometrial cancer stem cells hypothesis.Revisit dietary fiber on colorectal cancer: butyrate and its role on prevention and treatment.Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review.Cholangiocarcinoma: from molecular biology to treatment.The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation.Combined dual effect of modulation of human neutrophils' oxidative burst and inhibition of colon cancer cells proliferation by hydroxycinnamic acid derivatives.Ascorbic acid and colon cancer: an oxidative stimulus to cell death depending on cell profile.Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma.New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin.Effects of X-radiation on lung cancer cells: the interplay between oxidative stress and P53 levels.Influence of P53 on the radiotherapy response of hepatocellular carcinoma.Selective cytotoxicity and cell death induced by human amniotic membrane in hepatocellular carcinoma.Novel 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine fused chlorins as very active photodynamic agents for melanoma cells.Liver diseases: what is known so far about the therapy with human amniotic membrane?Metabolic effects of hypoxia in colorectal cancer by 13C NMR isotopomer analysis.Targeting triple-negative breast cancer cells with 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles.Evaluation of a (99m) Tc-labelled meso-bisphenylporphyrin as a tumour image agent.Effect of amniotic membrane proteins in human cancer cell lines: an exploratory study.Microenvironment influence on human colon adenocarcinoma phenotypes and matrix metalloproteinase-2, p53 and β-catenin tumor expressions from identical monoclonal cell tumor in the orthotopic model in athymic nude rats.Beyond the limits of oxygen: effects of hypoxia in a hormone-independent prostate cancer cell line.2-Bromo-5-hydroxyphenylporphyrins for photodynamic therapy: photosensitization efficiency, subcellular localization and in vivo studies.Hepatocellular carcinoma and chemotherapy: the role of p53.Cytotoxicity of ascorbic acid in a human colorectal adenocarcinoma cell line (WiDr): in vitro and in vivo studies.Synthesis of new 2-galactosylthiazolidine-4-carboxylic acid amides. Antitumor evaluation against melanoma and breast cancer cells.99mTc(I)/Re(I) tricarbonyl complexes for in vivo targeting of melanotic melanoma: Synthesis and biological evaluation.Radiolabelling of ascorbic acid: a new clue to clarify its action as an anticancer agent?Chiral 6-hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: novel antitumor DNA monoalkylating agents.Hypoxia-induced redox alterations and their correlation with 99mTc-MIBI and 99mTc-HL-91 uptake in colon cancer cells.In vitro photodynamic activity of 5,15-bis(3-hydroxyphenyl)porphyrin and its halogenated derivatives against cancer cells.
P50
Q28077283-C1646344-4D93-4FA2-AFDF-2FD6A4CC7E4EQ33489148-E74F9463-AB37-4086-A61B-9AFE87B9F914Q37516375-AFD103E8-FB76-409A-AFC3-E2F21C260A70Q37736963-6B22E358-C228-4BA1-AF1B-AD3B5CAA0EB0Q37871939-50E23A88-E9A8-4A35-A4AC-B28750C893E9Q38010638-D504AA6B-94C6-4770-9179-84CB2721FA43Q38213800-660BDCE8-620E-494D-9927-FEF0DA923980Q38314528-A4D225C9-FA3F-4B93-9B96-7225620D8604Q38493204-8C10B625-C48B-4191-A7A0-58E12B53611DQ38540827-8AD9F513-7D4D-4090-8D60-1508922D648EQ38557171-CA53870F-2842-43A9-A07A-B4CA8F3AD931Q38557172-8DAE9860-E766-4546-B9B2-D27577690B9DQ38564818-A89F2096-0931-4E1C-B31D-EC24606A4D5EQ38565503-F88ECC61-C821-4E30-B6E6-864C4F1507ABQ38597008-AD04D09A-1217-4843-98A3-B07753524CE7Q38730343-3D34CF23-0345-4B75-9670-A472CD9339BEQ38764940-99BE19B3-1FFE-4B71-A536-8227E88660CAQ38777806-837B0631-D326-42F0-95E6-D48423A7778AQ38787238-CA2A1BAE-59B7-4DCA-A26E-37A4F20F4000Q38788907-AE772AFC-00E9-47A6-BBB1-A30091765359Q38818565-FBF7CF88-960B-4711-84EE-83882D3582E4Q38822712-9BA6DD4E-F990-44CC-84E6-643BF5B5DF07Q38824357-8337F574-A8EC-466E-9B4A-5C683C766CEFQ38834482-2316AE48-17F7-483A-A7A4-629EDDAE331BQ38934348-C3964090-5F47-449D-941D-19D8EDB176A7Q38968639-BCB5F5FC-EE22-4C8C-876B-51329461E56EQ39002877-62D5463B-4ECF-4DFC-AE30-8B540ED3CEB1Q39014906-2F3F7A78-11EA-4037-A39C-85C020A2F996Q39020188-6F73BFD6-0230-4020-9B59-7C596C3C4A79Q39044766-1162A2DE-6D51-421D-9DFF-D50FB8DD7112Q39069174-3669D2A1-63F4-4489-8C31-220F99292D8AQ39184734-CB0AE85E-47D7-476F-80ED-544462B57361Q39222765-FE219B5D-20A8-4C8E-BDD6-39DBD0E8A7EFQ39279729-4DB410EA-4181-43AE-8D97-0A179570E4A8Q39353511-D338B8E8-7130-45BC-99A8-A0A7805559B0Q39383884-BEE5BE97-CE42-40F4-A570-E62CF5E4F226Q39405869-35EDBF7D-53DC-47A8-8CD9-8580B05664EFQ39668177-3721BE15-B2A7-4DB4-B170-61A1E8952487Q39740275-71A3BD28-C425-4CA7-9AA3-B881A95615EDQ39776211-87680160-B910-4D3A-8448-83F02E7BC862
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ana Margarida Abrantes
@ast
Ana Margarida Abrantes
@en
Ana Margarida Abrantes
@es
type
label
Ana Margarida Abrantes
@ast
Ana Margarida Abrantes
@en
Ana Margarida Abrantes
@es
altLabel
Ana M Abrantes
@en
Margarida Abrantes
@en
prefLabel
Ana Margarida Abrantes
@ast
Ana Margarida Abrantes
@en
Ana Margarida Abrantes
@es
P1053
A-4899-2012
G-6913-2018
P106
P1153
26029747600
P21
P31
P3829
P496
0000-0003-4185-7871